Medtronic (NYSE: MDT) has named Jorie Soskin as its new VP and GM of its TAVR and Congenital Heart businesses.

Analyst Travis Steed of Bank of America Securities maintained a Buy rating on Medtronic (MDT – Research Report), retaining the price ...

Specifically, Medtronic's diabetes and neuromodulation products may be poised for breakout growth, and the company's up-and-coming products in various stages of development offer promise as well.

Medtronic Chairman and CEO Geoffrey Martha discusses Johnson & Johnson acquiring V-Wave on 'The Claman Countdown.' 14 Things To Avoid Ordering At Wendy's And Why I'm 31, single and just received a ...

Strategics tend to invest in med-tech companies they are looking to acquire or could be acquired. Furthermore, companies like ...

Medtronic (NYSE: MDT) today announced the publication of its novel approach to studying adaptive deep brain stimulation (aDBS ...

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Medtronic (MDT – Research Report), with a ...

Medtronic's business is diversified. The company boasts dozens of devices across four main segments: Medical surgical, neuroscience, cardiovascular, and diabetes. Though Medtronic records ...

Shares of Medtronic PLC climbed toward a three-month ... amid strength in its diabetes and cardiovascular business. The company raised the lower ends of its full-year guidance ranges for both ...

Shares of Medtronic PLC MDT advanced 1.52% to $89.47 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 1.70% to 5,713.64 ...

Medtronic delivered a strong first-quarter ... in 2023. This helped the Diabetes segment's organic sales increase by 12.6%. This recovery is particularly important. Weakness in the Diabetes ...

The Ireland-based company also eyes growth across segments such as diabetes and devices for heart disease-focused surgeries. Medtronic also remains "on the hunt" for the right tuck-in deals.